| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2b data readout example | ESK-001 (next-generation oral TYK2 inhibitor) systemic lupus erythematosus (SLE) | Phase 2b | β | Small Molecules | Immunology | ||
phase 2b data readout example | ESK-001 (next-generation oral TYK2 inhibitor) systemic lupus erythematosus (SLE) | Phase 2b | β | Small Molecules | Immunology | ||
phase 2b data readout example | ESK-001 (next-generation oral TYK2 inhibitor) systemic lupus erythematosus (SLE) | Phase 2b | β | Small Molecules | Immunology |
Recent Updates
Recently added Catalysts
Alumis Inc.$24.76
+0.27 (+1.1%)
B 60Pipeline Score Fair Value Pharma Β· Commercial
Market Cap
2.81 B
EPS
-1.92
P/E Ratio
-
Value Trade
23.14 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.74 M
R&D Expenses
81.54 M
Operating CF
-87.08 M
Total Assets
671.59 M
Total Liabilities
104.57 M
Equity
567.02 M
D/E Ratio
12,345
-2.35 %
Week
-13.07 %
1 Month
-22.87 %
3 Month
221.46 %
6 Month
63.11 %
5 Year
63.11 %
All Time
Cash Data
Cash Position
569.55 M
Monthly Burn
29.03 M
Runway
18.5 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
430.02 K
52 Week Range
2.76 - 30.60
% held by Insiders
32.2 %
% held by Institutions
66.17 %
Enterprise Value
2.32 B
Total Shares
123.16 M
Short %
12.81 %
Float Shares
71.06 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B60
Pipeline Score $3.9B
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.4x
rNPV / MCap Top 89%
Small Cap (rank 101 of 905)
Percentile RankAlumis Inc. holds a solid B-grade pipeline (60/100), with $6.3B risk-adjusted pipeline value, led by envudeucitinib in Plaque Psoriasis (Phase 3), across $82B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| envudeucitinib Small molecule | Plaque Psoriasis | Phase 3 | NCT05739435 | 58% | $5.0B | ACTIVE NOT_RECRUITING | 3,619 | AVERAGE | C (52) | Dec 30, 2026 | LOW_RISK | LOW Jun 16, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
envudeucitinib | moderate-to-severe plaque psoriasis,systemic lupus erythematosus | Phase 2 | 2025-11-14 | |||
envudeucitinib | moderate-to-severe plaque psoriasis,systemic lupus erythematosus | Phase 2 | 2025-11-14 | |||
envudeucitinib | moderate-to-severe plaque psoriasis,systemic lupus erythematosus | Phase 2 | 2025-11-14 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)Β·9 selling (1 exited)Β·2 unchanged
Hedge Funds invested in ALMS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ALMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALMS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ALMS Institutional Ownership Trends
Current Insider %
5.20%
β+0.00%
Current Institutional %
62.40%
β+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALMSAlumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements - Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Ac
Alumis Inc. reported its financial results for Q1 2026 and highlighted key developments in the clinical performance of envudeucitinib, a novel treatment for moderate-to-severe plaque psoriasis. Phase 3 trial data presented at the American Academy of Dermatology Annual Meeting demonstrated significant improvements in skin clearance and patient-reported quality-of-life measures. The company plans to submit a New Drug Application (NDA) for envudeucitinib in Q4 2026 and anticipates pivotal data for treating systemic lupus erythematosus in Q3 2026. Overall, the results reinforce Alumis' confidence in envudeucitinib's ability to reshape psoriasis therapy.
Read more βALMSAlumisβ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Alumis Inc. announced promising results from its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib, a selective TYK2 inhibitor for moderate-to-severe plaque psoriasis. The trials demonstrated significant skin clearance and improvements in quality of life, with a favorable safety profile. The company plans to submit a New Drug Application to the FDA later this year.
Read more βALMSAlumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Alumis Inc. reported strong financial results for 2025, highlighting successful Phase 3 trials for envudeucitinib in moderate-to-severe plaque psoriasis. The drug demonstrated significant skin clearance and symptom improvement, with a favorable safety profile. Alumis plans to submit a New Drug Application (NDA) for envudeucitinib in the second half of 2026 and anticipates pivotal data for systemic lupus erythematosus in Q3 2026.
Read more βALMSAlumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
Alumis Inc. has announced that the results from its Phase 3 ONWARD clinical trials evaluating envudeucitinib for moderate-to-severe plaque psoriasis will be presented orally at the 2026 American Academy of Dermatology Annual Meeting. Additionally, a biomarker analysis from the Phase 2 STRIDE trial will be showcased as an e-poster. The presentations are set for March 28, 2026, with a follow-up investor webcast scheduled the following day to review the ONWARD trial data. Envudeucitinib, a next-generation TYK2 inhibitor, is also under evaluation for other immune-mediated diseases.
Read more βALMSAlumis to Present at the Leerink Partners Global Healthcare Conference
Alumis Inc. will present at the Leerink Partners Global Healthcare Conference on March 9, 2026. CEO Martin Babler will participate in a fireside chat, which will be available via live webcast. The company focuses on developing targeted therapies for immune-mediated diseases, including oral tyrosine kinase 2 inhibitors and other innovative treatments.
Read more βALMSAlumis to Participate in Upcoming February Investor Conferences
Alumis Inc. has announced its participation in several upcoming investor conferences. The company, known for developing next-generation targeted therapies for immune-mediated diseases, aims to enhance patient health outcomes. Their pipeline includes oral tyrosine kinase 2 inhibitors and other innovative treatments. Webcast replays will be available on their website for 90 days.
Read more βALMSAlumis Announces Closing of Upsized Public Offering and Full Exercise of Underwritersβ Option to Purchase Additional Shares
Alumis Inc. has successfully closed an upsized public offering of 20,297,500 shares of common stock, raising approximately $345.1 million. The offering included the full exercise of the underwriters' option to purchase an additional 2,647,500 shares at a price of $17.00 per share. The offering was conducted under a previously filed shelf registration statement and managed by several financial institutions. Alumis is focused on developing targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform and a promising pipeline.
Read more βALMSAlumis Announces Pricing of Upsized Public Offering of Common Stock
Alumis Inc. has announced the pricing of an upsized public offering of 17,650,000 shares of its common stock at a price of $17.00 per share, totaling approximately $300 million in gross proceeds. The offering is expected to close on January 9, 2026, barring any unforeseen circumstances. Alumis has also granted underwriters a 30-day option to purchase additional shares. This move underscores the company's efforts to fund the development of its innovative therapies for immune-mediated diseases.
Read more βALMSAlumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
Alumis Inc. will announce topline data from its Phase 3 ONWARD clinical program for envudeucitinib, targeting moderate-to-severe plaque psoriasis, on January 6, 2026. A conference call and webcast will follow to discuss the results. The company aims to improve patient outcomes with its next-generation therapies.
Read more βALMSAlumis Announces Proposed Public Offering of Common Stock
Alumis Inc. has announced a proposed underwritten public offering of $175 million worth of common stock, with an additional option for underwriters to purchase another $26.25 million in shares. The offering aims to fund the development of its pipeline of targeted therapies for immune-mediated diseases. The company has filed a registration statement with the SEC for the offering, which remains subject to market conditions and uncertainties regarding completion.
Read more βALMSAlumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program - Both Phase 3 trials met all primary and secondary endpoints with high statistical signific
Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envudeucitinib, a selective TYK2 inhibitor for moderate-to-severe plaque psoriasis. The trials demonstrated high statistical significance in achieving primary endpoints, with notable skin clearance in patients. Approximately 65% of participants achieved PASI 90 at Week 24. Envudeucitinib is expected to transform oral psoriasis therapy and Alumis plans to submit a New Drug Application to the FDA in 2026.
Read more βALMSAlumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Alumis Inc. reported its financial results for Q3 2025, highlighting both its financial challenges and significant upcoming milestones in drug development. The company anticipates key data from its Phase 3 ONWARD trial for envudeucitinib in moderate-to-severe plaque psoriasis in early 2026 and from its Phase 2b LUMUS study in systemic lupus erythematosus later in the year. Despite facing a net loss of $110,752 for the quarter, Alumis remains optimistic about its robust pipeline and potential market opportunities for its drugs.
Read more βALMSAlumis to Participate in Upcoming November Investor Conferences
Alumis Inc. has announced its participation in several upcoming investor conferences in November. The company focuses on developing next-generation targeted therapies for immune-mediated diseases, including oral tyrosine kinase inhibitors and other innovative treatments. Their participation highlights their commitment to engaging with investors and showcasing their advancements in biopharma.
Read more βALMSTransform Therapies. Reimagine Lives. September 2025 Corporate Presentation 2© Alumis Forward-Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, i
Alumis is advancing its clinical pipeline with several near-term milestones expected, including the initiation of Phase 2 trials for its A-005 candidate in multiple sclerosis. The company also focuses on Lonigutamab, which targets IGF-1R and has been shown to potentially have a differentiated safety profile, critical to addressing significant unmet needs in thyroid eye disease (TED). Additionally, Alumis plans to speed up its ongoing Phase 2b program for systemic lupus erythematosus (SLE) while aiming for accelerated regulatory pathways. A positive initial response in clinical trials bolsters the strategic focus on not only immediate therapies but also future-market potential.
Read more βALMSAlumis to Participate in Upcoming September Investor Conferences
Alumis Inc. (Nasdaq: ALMS) has announced its participation in several upcoming investor conferences in September 2025. The events include the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Investment Conference, and the Baird Global Healthcare Conference, along with a virtual forum hosted by Stifel. This strategy aims to enhance the company's visibility and connect with potential investors regarding its therapies for immune-mediated diseases.
Read more βALMSAlumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Alumis Inc. reported its financial results for Q2 2025, highlighting the completion of enrollment in pivotal Phase 3 and Phase 2b clinical trials for envudeucitinib. The company anticipates topline data readouts in early 2026 and Q3 2026, respectively. Additionally, Alumis completed a merger with ACELYRIN to bolster its financial standing and advance its immunology pipeline. The company has a robust cash position expected to sustain operations through 2027.
Read more βALMSAlumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
Alumis Inc. has completed patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor aimed at treating systemic lupus erythematosus (SLE). The trial enrolled 408 patients and is designed to assess improvements in disease activity over 48 weeks. Topline results are anticipated in Q3 2026, marking a significant step for both the company and the lupus community.
Read more βALMSAlumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
Alumis Inc. has promoted Sanam Pangali to Chief Legal Officer and Corporate Secretary, succeeding Sara Klein. Pangali, who previously served as Senior Vice President, Legal, will oversee legal and compliance functions. The announcement highlights the company's commitment to advancing its pipeline of targeted therapies for immune-mediated diseases.
Read more βALMSAlumis to Present at the Jefferies Global Healthcare Investor Conference
Alumis Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2025. CEO Martin Babler will discuss the company's advancements in targeted therapies for immune-mediated diseases. The event will be accessible via a live webcast, with a replay available for 90 days. Alumis is developing a range of innovative treatments, including oral tyrosine kinase inhibitors.
Read more βALMSAlumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
Alumis Inc. has completed patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, targeting moderate-to-severe plaque psoriasis. The program includes over 1,700 patients across two trials, with topline results expected in early Q1 2026. ESK-001 is designed as a next-generation oral TYK2 inhibitor, aiming to improve treatment options for patients.
Read more βALMSAlumis Completes Merger with ACELYRIN
Alumis Inc. has successfully completed its merger with ACELYRIN, enhancing its financial position and extending its cash runway into 2027. Each ACELYRIN stockholder will receive shares of Alumis common stock, as ACELYRIN will no longer be listed on NASDAQ. The merger is expected to support Alumis' late-stage pipeline and facilitate upcoming data readouts.
Read more βALMSAlumis Completes Merger with ACELYRIN Establishes leading clinical stage biopharma company with differentiated portfolio of therapies and strong balance sheet
Alumis Inc. has successfully completed its merger with ACELYRIN, creating a leading clinical stage biopharma company focused on targeted therapies for immune-mediated diseases. ACELYRIN stockholders will convert their shares into Alumis common stock, as ACELYRIN ceases trading. Alumis' CEO, Martin Babler, expressed enthusiasm about the merger's benefits for both the company's portfolio and its patient base, along with a projected cash runway into 2027. The merger positions Alumis to advance its pipeline of therapies effectively.
Read more βALMSAlumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
Alumis Inc. (Nasdaq: ALMS) reported financial results for Q1 2025, emphasizing their progress in clinical trials, particularly with ESK-001, a TYK2 inhibitor targeting moderate-to-severe plaque psoriasis. The company is on track to release pivotal Phase 3 data in early 2026. Additionally, Alumis is in the process of merging with ACELYRIN, which is expected to enhance their clinical pipeline and provide financial flexibility. They highlighted recent collaborations and the development of multiple therapeutic candidates for immune-mediated diseases.
Read more βALMSAlumis Stockholders Approve Merger with ACELYRIN
Alumis Inc. has announced that its stockholders approved the merger with ACELYRIN, INC. at a Special Meeting. The merger is expected to close in the second quarter of 2025, pending customary closing conditions. Alumis aims to leverage the merger to enhance its portfolio and advance treatments for immune-mediated diseases.
Read more βALMSAlumis and ACELYRIN Announce Amended Merger Agreement ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately
Alumis and ACELYRIN have announced an amended merger agreement that enhances the ownership percentage for ACELYRIN stockholders through a revised exchange ratio. Under the new terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN, resulting in approximately 48% ownership of the combined company. The merger aims to create a stronger entity capable of maximizing the value of various late-stage assets, with stockholder meetings scheduled for May 13, 2025, to finalize approvals. Both companies remain optimistic about the benefits of the transaction.
Read more βALMSAlumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Alumis Inc. and ACELYRIN, INC. have filed a definitive proxy statement for their proposed merger, with stockholders encouraged to vote in favor. The merger is expected to create a robust new entity focused on innovative treatments for immune-mediated diseases, with significant capital backing and a strong pipeline. Stockholders meetings are scheduled for May 13, 2025, and the transaction is anticipated to close in the second quarter of 2025, pending necessary approvals.
Read more βALMSAlumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan - Alumis to receive $40 million in upfront and near-term co-development payments, with potential for appr
Alumis Inc. has announced a collaboration and licensing agreement with Kaken Pharmaceutical for the development of ESK-001, an oral TYK2 inhibitor for dermatological indications in Japan. This agreement includes an upfront payment of $40 million, with a potential total of approximately $140 million in milestone payments. Kaken will oversee the clinical development and commercialization of ESK-001 within Japan, while Alumis retains rights in other regions. The partnership aims to enhance the availability of ESK-001, which has demonstrated positive clinical data.
Read more βALMSAlumis Reports Year End 2024 Financial Results and Highlights Recent Achievements - Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led
Alumis Inc. has reported its financial results for the year ended December 31, 2024, highlighting significant achievements including the presentation of clinical data for its oral TYK2 inhibitors ESK-001 and A-005. The company anticipates critical milestones in the next 12-18 months, including data from the Phase 3 ONWARD program in Q1 2026 and commencement of a Phase 2 trial for A-005 in multiple sclerosis in 2H 2025. Alumis has also announced a merger agreement with ACELYRIN, aiming to enhance its portfolio and extend its operational runway into 2027. Overall, the company is focused on improving outcomes for patients with immune-mediated diseases.
Read more βALMSTransform Therapies. Reimagine Lives. March 2025 Corporate Presentation Supplemental Materials 2 Alumis Forward - Looking Statements This presentation contains forward looking statements within the meaning of federal sec
Alumis Inc. has released a corporate presentation discussing its proposed merger with ACELYRIN, Inc. This presentation outlines various forward-looking statements regarding implementation plans and potential risks associated with the merger. Key areas of focus include the anticipated completion of the transaction, required approvals, and the ability of both companies to maintain operational integrity during the merger process. The presentation highlights that the statement's reliability is subject to uncertainties that may affect actual outcomes.
Read more βALMSAlumis to Present at Leerink's 2025 Global Healthcare Conference
Alumis Inc. announced its participation in the upcoming Leerink's 2025 Global Healthcare Conference, where CEO Martin Babler will lead a fireside chat. The company is focused on developing oral therapies for immune-mediated diseases using a precision approach. Their lead candidate, ESK-001, is designed to treat moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Alumis is also exploring additional therapies for neuroinflammatory conditions, utilizing its proprietary data analytics platform for drug development.
Read more βALMSLate-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis - ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2)
Alumis Inc. has announced promising 52-week data from the Phase 2 open-label extension trial for ESK-001, an oral therapy targeting moderate-to-severe plaque psoriasis. Presented at the 2025 AAD Annual Meeting, the results indicate significant improvements in clinical responses over time, with high patient satisfaction regarding itch control and quality of life. The treatment also showed a good safety profile without new adverse findings. Alumis plans to further evaluate ESK-001 in its Phase 3 ONWARD studies, which are currently ongoing.
Read more βALMSAlumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet SOUTH SAN FRANCISCO, Calif. and
Alumis Inc. (Nasdaq: ALMS) and ACELYRIN, Inc. (Nasdaq: SLRN) have reaffirmed their commitment to merge in an all-stock transaction. The merger aims to form a leading clinical stage biopharmaceutical company specializing in immune-mediated diseases, capitalizing on both companies' strengths, including a diverse late-stage portfolio and a strong financial foundation. The transaction is expected to close in the second quarter of 2025, subject to stockholder approvals and other customary closing conditions. Both companies anticipate that this merger will unlock significant value and drive innovation for stakeholders.
Read more βALMSAlumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
Alumis Inc. announced that it will present 52-week data from its Phase 2 open-label extension study of ESK-001 at the 2025 AAD Annual Meeting. ESK-001 is a next-generation oral TYK2 inhibitor designed for treating moderate-to-severe psoriasis. Additionally, the company expects to release topline data from its Phase 3 ONWARD clinical program in Q1 2026, ahead of previous schedules, indicating strong progress in its clinical development efforts.
Read more βALMSAlumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
Alumis Inc. presented new Phase 1 data on A-005, a CNS-penetrant TYK2 inhibitor, at the ACTRIMS Forum 2025. The data indicate that A-005 effectively inhibits TYK2 signaling linked to neuroinflammatory conditions and was well tolerated in a Phase 1 trial involving 135 healthy participants. The company plans to advance A-005 into a Phase 2 trial for multiple sclerosis in the latter half of 2025, leveraging its innovative potential to treat various neurodegenerative diseases.
Read more βALMSAlumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Alumis Inc. (Nasdaq: ALMS) announced that its CEO, Martin Babler, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. Alumis is focused on developing oral therapies aimed at improving the lives of patients with immune-mediated diseases. Their leading candidate, ESK-001, targets conditions such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus. The company also utilizes a proprietary data analytics platform to support its drug discovery efforts.
Read more βALMSAlumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases Topline da
Alumis Inc. and ACELYRIN, INC. have announced a definitive merger agreement, combining their resources to form a late-stage clinical biopharma company. The merger, conducted through an all-stock transaction, is expected to close in the second quarter of 2025, pending stockholder approval. The combined company will mainly focus on developing innovative therapies for immune-mediated diseases, leveraging its strong cash position of approximately $737 million. Both companies aim to advance a robust pipeline of therapeutics, with key data readouts anticipated in the coming years.
Read more βALMSAlumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Alumis and ACELYRIN have announced a definitive merger agreement to create a late-stage clinical biopharma company focused on developing therapies for immune-mediated diseases. The merger will provide the combined company with a pro forma cash position of approximately $737 million, enabling expansion into late-stage clinical development. Alumis will continue to lead the new entity, leveraging its existing expertise and pipeline, while integrating ACELYRIN's assets including lonigutamab. The transaction is expected to close in the second quarter of 2025, pending stockholder approval.
Read more βALMSAlumis Strengthens Leadership Team with Key Appointments
Alumis Inc. has announced key leadership appointments to strengthen its team as it transitions to a late-stage biopharmaceutical company. Jack Danilkowicz has been appointed Chief Commercial Officer, bringing significant experience in commercial strategies for novel medicines. Sara Klein has been promoted to Chief Legal Officer, continuing her role in overseeing legal matters and corporate governance. These appointments are aimed at enhancing the companyβs capabilities as it advances its clinical pipeline, particularly the TYK2 inhibitor ESK-001.
Read more βALMSAlumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
Alumis Inc. has announced positive Phase 1 clinical trial results for its CNS-penetrant TYK2 inhibitor, A-005, which showed well-tolerated safety and pharmacokinetic profiles in healthy participants. The trial found that A-005 could effectively cross the blood-brain barrier, indicating its potential for treating conditions like multiple sclerosis. The company plans to move forward with a Phase 2 clinical trial anticipated in the second half of 2025 to further evaluate A-005's therapeutic efficacy in patients. The promising data positions A-005 as a significant candidate for treatment in neuroinflammatory and neurodegenerative diseases.
Read more βALMSAlumis Presents Data Highlighting ESK-001βs Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
Alumis Inc. announced that it will present data on ESK-001, a selective oral TYK2 inhibitor, at the ACR Convergence 2024. The data suggest that ESK-001 effectively downregulates key biomarkers and cytokines associated with systemic lupus erythematosus (SLE). The company is advancing its Phase 2b LUMUS study, with expectations to report top-line data in 2026. ESK-001 is also being evaluated in a Phase 3 trial for moderate-to-severe plaque psoriasis, demonstrating its broad therapeutic potential.
Read more βALMSAlumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements - Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal
Alumis Inc. reported its third quarter 2024 financial results, revealing advancements in clinical programs, including the ongoing Phase 3 ONWARD trials for ESK-001 in plaque psoriasis and Phase 2b trials in systemic lupus erythematosus. Financial results indicated a net loss of $93,117, attributed to increased operating expenses. The company's strategic focus on maximizing TYK2 inhibition promises a differentiated oral treatment approach. Upcoming data readouts are anticipated, including important results from both ESK-001 and A-005 trials in early 2025.
Read more βALMSAlumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Alumis Inc. (Nasdaq: ALMS) has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference, scheduled for November 12, 2024, in Boston, MA. CEO Martin Babler will engage in a fireside chat during the event. The company is focused on developing oral therapies for immune-mediated diseases and is advancing its lead product candidate, ESK-001, an allosteric inhibitor of TYK2, aimed at treating moderate-to-severe plaque psoriasis and systemic lupus erythematosus. The event will be accessible via a live webcast on the Alumis website, with an archived replay available for 90 days afterward.
Read more βALMSAlumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psorias
Alumis Inc. has reported its financial results for the second quarter of 2024, highlighting significant advancements in its clinical programs. Notably, the company initiated patient dosing in the Phase 3 ONWARD clinical trial for ESK-001, targeting moderate-to-severe plaque psoriasis, alongside the initiation of a Phase 1 trial for A-005. Alumis successfully raised $250 million through an IPO and private placement, enhancing its financial stability. Despite these achievements, the company reported a net loss of $56.5 million, reflecting ongoing operational challenges.
Read more βALMSAlumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
Alumis Inc. has launched the ONWARD Phase 3 clinical program for ESK-001, an oral TYK2 inhibitor aimed at treating moderate-to-severe plaque psoriasis. This program includes two identical 24-week trials, supported by positive Phase 2 results that indicate ESK-001 is generally well tolerated and effective. Alongside efficacy evaluations, the program intends to assess long-term safety and response durability. Data from these trials will play a crucial role in potential regulatory submissions expected to commence in 2026.
Read more βALMSAlumis Announces Pricing of Initial Public Offering
Alumis Inc. has announced the pricing of its initial public offering, set at $16 per share, with a total of 13,125,000 shares being offered. The offering, which is expected to close on July 1, 2024, aims to raise approximately $250 million. In addition, a private placement of 2,500,000 shares to AyurMaya Capital Management is also planned. Trading on Nasdaq is scheduled to begin on June 28, 2024, under the ticker 'ALMS'.
Read more βALMSAlumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
Alumis Inc. has announced the commencement of dosing in a Phase 1 clinical trial for A-005, a novel CNS penetrant TYK2 inhibitor targeted at neuroinflammatory and neurodegenerative diseases. This trial will evaluate the safety, tolerability, and pharmacokinetics of A-005 in healthy volunteers, supported by promising preclinical results. The drug demonstrated high potency and the ability to effectively cross the blood-brain barrier, indicating potential effectiveness for conditions such as multiple sclerosis and Parkinson's Disease.
Read more βALMSAlumis to Participate in the 2024 Leerink Partners Global Biopharma Conference
Alumis Inc. is set to participate in the 2024 Leerink Partners Global Biopharma Conference, with investor meetings scheduled for March 12, 2024, in Miami. The clinical-stage biopharmaceutical company focuses on developing oral therapies aimed at treating immune-mediated diseases. Their lead candidate, ESK-001, is a selective TYK2 inhibitor currently evaluated for multiple severe conditions. Additionally, a potential first-in-class product, A-005, is anticipated to enter Phase 1 trials in early 2024.
Read more βALMSAlumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
Alumis Inc. announced positive results from a Phase 2 clinical trial of ESK-001, an allosteric TYK2 inhibitor for moderate-to-severe plaque psoriasis. The trial met primary endpoints with significant improvements in the Psoriasis Area and Severity Index (PASI) at all tested doses. Continued favorable safety profiles and increasing efficacy over time were observed, particularly at the highest dose. Following this success, Phase 3 clinical trials are planned for the second half of 2024.
Read more βALMSAlumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
Alumis announced an upsized $259 million Series C financing to support the clinical development of its lead candidate, ESK-001, and other pipeline programs. The funding will primarily assist in initiating pivotal Phase 3 trials for ESK-001 in moderate to severe plaque psoriasis and supporting ongoing Phase 2 trials for SLE and uveitis. With participation from multiple prestigious investors, the financing signals substantial confidence in Alumis' potential to transform treatments for immune-mediated diseases.
Read more βALMSAlumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting
Alumis Inc. has announced that it will present late-breaking data from its Phase 2 clinical trial of ESK-001, a selective oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, at the American Academy of Dermatology Annual Meeting. The presentations will include both efficacy and safety results, as well as pharmacokinetic and pharmacodynamic data. Following the Phase 2 data presentation, the company will host a virtual investor event to discuss the results.
Read more βALMSAlumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS
Alumis Inc. has unveiled positive preclinical data for its allosteric TYK2 inhibitor, A-005, targeting neuroinflammatory diseases such as multiple sclerosis and Parkinson's Disease. The data, presented at the ACTRIMS 2024 forum, shows A-005's effectiveness in inhibiting TYK2 pathway activation and its potential to improve clinical outcomes in experimental autoimmune encephalomyelitis models. The company plans to initiate a Phase 1 clinical trial in the first half of 2024, further underscoring confidence in A-005's therapeutic potential.
Read more βALMSAlumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis
Alumis Inc. has initiated patient dosing in two Phase 2 clinical trials for ESK-001, targeting systemic lupus erythematosus (SLE) and uveitis. The LUMUS trial is designed for 388 patients with moderately to severely active SLE, while OPTYK-1 focuses on noninfectious uveitis. ESK-001 is touted as a highly selective and potentially best-in-class allosteric TYK2 inhibitor, aiming to address significant unmet needs in these conditions. Both trials employ rigorous methodologies, with the potential for informing future applications of ESK-001 in other autoimmune indications.
Read more βCompetitive Position
How ALMS ranks across every disease it competes inCompetitive Position is a premium feature
See how ALMS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial